- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04445129
Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a non-drug study including participants with NT1 and healthy participants using devices designed for at-home assessments. The study will assess whether a portable EEG device provides an EEG signal comparable to inpatient nPSG. The frequency and characteristics of wake and sleep patterns and transitions over multiple nights will also be characterized. Participants with NT1 who will complete the study TAK-994-1501 (NCT04096560) will be eligible to enter the current study following the appropriate washout period (60 days).
The study will enroll approximately 32 participants (16 participants with NT1 and 16 healthy participants). Participants will be enrolled in the 2 groups:
- NT1 Participants
- Healthy Participants
This multi-center trial will be conducted in the United States. The overall time to participate in this study is approximately 8 days. The follow-up visit will occur on Day 10 and during this debrief, participants will answer a questionnaire on user experience (device comfort) for the wearable devices.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Stanford School of Medicine
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80918
- Delta Waves Sleep Disorders and Research Center
-
-
Florida
-
Clearwater, Florida, United States, 33765
- St Francis Medical Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- NeuroTrials Research, Inc.
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Fort Wayne Neurological Center
-
-
New York
-
Bronx, New York, United States, 10467
- Sleep Wake Disorders Center
-
-
North Carolina
-
Denver, North Carolina, United States, 28037
- Research Carolina Elite, LLC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45245
- Intrepid Research
-
Cincinnati, Ohio, United States, 45212
- CTI Clinical Trial and Consulting Services
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
Dublin, Ohio, United States, 43017
- Ohio Sleep Medicine Institute
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Bogan Sleep Consultants, LLC
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Sleep Therapy & Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Has access to at-home Wi-Fi and can add an internet-ready device with assistance.
- Body mass index (BMI) between greater than equal to (>=) 18.0 and less than or equal to (<=) 40.0 kilogram per square meter (kg/m^2) at the screening visit.
- Must have regular sleep-wake habits (example, routinely spending 6.5 to 8.5 hours sleeping nightly, not oversleeping by more than 2 hours on weekends, that is, total sleep not more than approximately 10.5 hours) as determined by investigator interviews and confirmed in accelerometry/actigraphy records obtained between screening and first visit (measured using a minimum of 10 day/night consecutive periods) and who regularly fall asleep between 9:30 PM and 12:00 AM (healthy participants only).
- Must not require use of sleep aids or must be willing to discontinue use of sleep aids for the duration of the study.
- Has completed the TAK-994-1501 study, the participant is eligible to enter the current study following the appropriate washout period (60 days).
Participants With NT1 Only:
- With NT1 who is drug-naïve may also be enrolled.
- With NT1 must present with subjective sleep complaint.
- With NT1 must have a diagnosis of NT1, as defined by the International Classification of Sleep Disorders, 3rd edition (ICSD-3) criteria.
Exclusion Criteria:
- Has a current diagnosis of cancer except for squamous or basal cell skin cancer.
- Has a nicotine or marijuana dependence that is likely to have an effect on sleep (example, a participant who routinely awakens at night to smoke) and/or an unwillingness to discontinue all smoking and nicotine use during the confinement portions of the study.
- Cannot maintain stable sleep environment at home, for example, due to young children not yet sleeping through the night or partners with disrupted sleep (example, shift workers).
- Undergoing current treatment for hepatitis B with interferon.
- Has a risk of suicide according to endorsement of Item 4 or 5 of the screening visit Columbia Suicide Severity Rating Scale (C-SSRS) or has made a suicide attempt in the previous 6 months.
- Has medical condition, such as past or current epilepsy, seizure, head injury/trauma, medically significant unstable cardiovascular, pulmonary, hepatic, renal, or gastrointestinal disease, that interferes with a normal sleep pattern or would preclude enrollment in the view of the investigator.
- Has a lifetime history of major psychiatric disorder, such as bipolar disorder or schizophrenia.
- As of the screening visit and throughout the study, the participant should not be a chronic caffeine user, as defined by an excessive (greater than [>] 600 milligram [mg]/day) caffeine intake per day.
- Has a medical disorder (other than narcolepsy), associated with excessive daytime sleepiness. This includes clinically significant obstructive sleep apnea or other sleep disturbances that has a significant impact on daytime sleepiness, confirmed by past PSG data (example, apnea hypopnea index >=10, periodic limb movement disorder index in sleep >=15) or a periodic limb movement disorder arousal index of >=10, or as evaluated on interview at the screening visit. Because nPSG data is obtained on Day 1, participants may be removed from study if they meet the above exclusion at the discretion of the principal investigator. Participants removed under this criterion will be replaced.
- At the time of screening the participant is being treated with nasal or oro-nasal positive airway pressure for any reason.
- Is currently being prescribed sodium oxybate or has been off of sodium oxybate for less than 4 weeks.
- Is using varenicline (Chantix).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Narcolepsy Type 1 Participants
Participants with NT1 on stable wake-promoting medications and exclusive of any sleep promoting medications will be fitted with the portable electrocardiogram (ECG) device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
|
Portable EEG device is lightweight and designed for nighttime wear.
Portable ECG device is waterproof and will be adhered to the chest of the participant.
Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
|
Healthy Participants
Participants who are healthy sex- and age (plus or minus 5 years)-matched controls will be fitted with the portable ECG device combined with wrist accelerometry and undergo a 2-night nPSG combined with the portable EEG device.
|
Portable EEG device is lightweight and designed for nighttime wear.
Portable ECG device is waterproof and will be adhered to the chest of the participant.
Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep State Scoring From nPSG and Portable EEG Device
Time Frame: up to 2 Nights
|
The concordance between EEG signals obtained from the portable EEG device with nPSG over 2 inpatient night stays will be assessed using data obtained during the inpatient setting from nPSG and a portable EEG device.
Scoring of sleep stages occur in 30-seconds epoch based on American Academy of Sleep Medicine (AASM) scoring rules.
The output from the nPSG and the portable EEG device will be hand scored for each participant, with the rater assigning 1 of 5 sleep/wake stages to each 30 second epoch 3 stages of non-REM (NREM) sleep (N1, N2, N3), rapid eye movement (REM), and wakefulness (W).
The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture.
nPSG will be used to as the comparator to the portable EEG device.
|
up to 2 Nights
|
Stage Shift Index (SSI) as Measured by Standard nPSG and EEG Device on Night 2
Time Frame: Night 2
|
SSI will be measured by standard nPSG and portable EEG device on Night 2 in the clinic.
SSI will be calculated as the number of transitions between any wake or sleep stage divided by hours of total sleep time.
The summary of the frequency of different stages of sleep transitions can be represented by SSI, which can be used to differentiate healthy participant from those with sleep pathology.
The correlation between the SSI as measured by the portable EEG device and by the nPSG will be analyzed for participants with NT1 and healthy controls.
The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture.
nPSG will be used as the comparator to the portable EEG device.
|
Night 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SSI as Measured by Standard nPSG and EEG Device During the Period at Home
Time Frame: Nights 3-7
|
SSI will be measured by portable EEG device on nights 3-7 at home.
SSI will be calculated as the number of transitions between any wake or sleep stage divided by hours of total sleep time.
The summary of the frequency of different stages of sleep transitions can be represented by SSI, which can be used to differentiate healthy participant from those with sleep pathology.
The SSI will be analyzed using the intrasubject correlation (intraclass correlation across different nights) in participants with NT1 and healthy participants.
The nPSG is a standardized procedure used to assess various sleep parameters, including sleep latency and sleep architecture.
|
Nights 3-7
|
Number of Microsleeps and State Transitions During the Maintenance of Wakefulness Tests (MWTs)
Time Frame: Day 2
|
Micro sleeps are defined as appearance of any stage of sleep arising out of wakefulness lasting from 3 seconds to less than or equal to (<=) 15 seconds and assessed on signals obtained from portable EEG device.
State transition refers to switch between wake and sleep.
MWT is a validated, objective measure used to measure excessive daytime somnolence (EDS) in clinical studies.
MWT evaluate a person's ability to remain awake under soporific conditions for a defined period.
Wakefulness will be measured indirectly by time to fall asleep using MWT.
Four 40-minute trials will be administered (each 4 session 40-minute MWT is considered as complete test).
Sleep onset is defined as first epoch of greater than 15 seconds of cumulative sleep in a 30-second epoch.
Trials are ended after 40 minutes if no sleep occurs/after unequivocal sleep, defined as 3 consecutive epochs of stage 1 sleep or 1 epoch of any other stage of sleep.
If no sleep has been observed, then latency is defined as 40 minutes.
|
Day 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Takeda Development Center Americas, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-994-0001
- U1111-1251-7993 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Portable EEG Device
-
Sunnybrook Health Sciences CentreRecruiting
-
United States Naval Medical Center, San DiegoNaval Health Research CenterCompletedPTSD | Anxiety | Trauma | Sleep DisordersUnited States
-
Yale UniversityButterfly Network, IncCompletedVoiding Disorders | Voiding DysfunctionUnited States
-
European e-Learning School in Obstetric AnesthesiaUniversity of Milano BicoccaCompletedObesity | Pregnancy RelatedItaly
-
NYU Langone HealthCompletedAttention Deficit Hyper ActivityUnited States
-
University of FloridaRecruitingCystic FibrosisUnited States
-
Kuopio University HospitalUniversity of Eastern FinlandCompletedAtrial Fibrillation | Heart Rate Fast | Heart Rate LowFinland
-
Laval UniversityCompletedDiabetes Mellitus, Type 2 | Physical Activity | MotivationCanada
-
United States Naval Medical Center, San DiegoThe Geneva FoundationWithdrawnHearing and Vestibular DisordersUnited States
-
Ohio State UniversityRecruitingCognitive DeclineUnited States